MRVI Q1 2022 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$244M+64.8% YoY

Gross Profit

$204M83.6% margin

Operating Income

$167M68.5% margin

Net Income

$67M27.4% margin

EPS (Diluted)

$1.20

QoQ Revenue Growth

+6.9%

Cash Flow

Operating Cash Flow

$162M

Free Cash Flow

$160M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$1.4B

Stockholders' Equity

$383M

Cash & Equivalents

$431M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$244M	$148M	+64.8%
Gross Profit	$204M	$117M	+74.9%
Operating Income	$167M	$91M	+83.5%
Net Income	$67M	$23M	+189.4%

Revenue Segments

Nucleic Acid Production Segment

$224M92%

Biologics Safety Testing Segment

$21M8%